Safety study in dogs at the University of Copenhagen

Panion develops an innovative gene therapy treatment for dogs with drug-resistant epilepsy. To move from preclinical studies and into the clinical phase with treatment of family dogs suffering from true epilepsy, the product must be shown to be safe for dogs. Adequate safety data for the investigators and

responsible hospital clinics must therefore be provided by Panion.

“We have started a new experimental dog study to produce the requested safety data and to expand our understanding of the product. The study is conducted under the lead of Associate Professor David Woldbye from University of Copenhagen, who is an expert in development of gene therapy for treatment of epilepsy.

The new data will supplement safety data from an existing dog study that was very encouraging”, says Anja Holm, CEO of Panion Animal Health AB.

The study runs in Q1 and Q2 of 2018, as previously announced. The outcome of the study will be announced as soon as available.

Anja E. H. Holm, CEO + 45-22 94 66 00

Bolaget ska utveckla och kommersialisera genterapi för behandling av epilepsiliknande tillstånd hos hundar och andra djur, samt utveckla och kommersialisera andra veterinärmedicinska produkter och nya behandlingsformer som kan ge sjuka djur bättre livskvalitet. Panion will develop and commercialize a gene therapy treatment for dogs with drug refractory epilepsy, and other new animal health products and treatments that improve the quality of life for animals suffering from chronic diseases.


Documents & Links